Daijiro Harada
Shikoku Cancer Center · 145 works · 2,387 citations · h-index 23
Top works
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
- Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
- The Role of STAT3 in Non-Small Cell Lung Cancer
- The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
- Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
- The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
- Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
- Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy
- JAK 2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation
- The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression
- Subpopulation of small‐cell lung cancer cells expressing CD 133 and CD 87 show resistance to chemotherapy
- A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
- Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
- Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors
- The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
- Clinical features and treatment of epidermal growth factor inhibitor‐related late‐phase papulopustular rash
- Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
- Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
- Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing